This project aims to develop, characterize, and validate a proof of concept for an innovative therapy for periodontal diseases (PDs), based on the combination of bimetallic oxide nanoparticles with antibacterial and antioxidant activity, capable of releasing a repositioned drug (a tetracycline, TC, selected for its immunomodulatory capacity), associated with a monoclonal antibody (tocilizumab, TCZ).
The developed therapy aims to surpass current therapies through the following innovations:
- Production of biodegradable nanoparticles with antibacterial and antioxidant activity, through a green, scalable, and licensable synthesis process;
-
Optimization of tetracycline selection for the modulation of periodontal diseases, through a drug repositioning strategy, with potential application in other immuno-inflammatory pathologies;
-
Fabrication of a multi-target approach by combining ZnOMgO nanoparticles with a selected tetracycline and tocilizumab, to increase therapeutic effectiveness;
-
Validation of biological functionality in an in vitro organotypic model and in a translational animal model of periodontal diseases.
